Multiple studies published in The Lancet Infectious Diseases journal show that GSK Bexsero could help improve protection against gonorrhea.

Two studies showed some cross protections from GSK Bexsero, designed to vaccinate against Neisseria meningitidis, against N gonorrhoeae.

A third study suggests that vaccination with Bexsero could be a cost-effective method of averting gonorrhea and impactful on public health.